In vivo fitness cost of the M184V mutation in multidrug-resistant human immunodeficiency virus type 1 in the absence of lamivudine.
about
Antiretroviral regimens for patients with HIV who fail first-line antiretroviral therapyViral quasispecies evolutionDynamics of HIV-1 quasispecies during antiviral treatment dissected using ultra-deep pyrosequencingLow-abundance HIV drug-resistant viral variants in treatment-experienced persons correlate with historical antiretroviral useTransmitted drug resistance in the CFAR network of integrated clinical systems cohort: prevalence and effects on pre-therapy CD4 and viral loadStanding genetic variation and the evolution of drug resistance in HIVCommunity HIV-1 drug resistance is associated with transmitted drug resistanceThe impact of wild-type reversion on transmitted resistance surveillance.Effect of raltegravir resistance mutations in HIV-1 integrase on viral fitnessSelect resistance-associated mutations in blood are associated with lower CSF viral loads and better neuropsychological performance.Replicative fitness costs of nonnucleoside reverse transcriptase inhibitor drug resistance mutations on HIV subtype C.Inferring HIV Escape Rates from Multi-Locus Genotype Data.Differential persistence of transmitted HIV-1 drug resistance mutation classes.From resistance to stimulation: the evolution of a virus in the presence of a dominant lethal inhibitory scaffolding protein.Similar replicative fitness is shared by the subtype B and unique BF recombinant HIV-1 isolates that dominate the epidemic in Argentina.Detection of HIV-1 dual infections in highly exposed treated patients.Clinical management of HIV drug resistance.It is time to consider third-line options in antiretroviral-experienced paediatric patients?Immune-mediated attenuation of HIV-1HIV-1 and HIV-2 reverse transcriptases: different mechanisms of resistance to nucleoside reverse transcriptase inhibitors.Vicriviroc resistance decay and relative replicative fitness in HIV-1 clinical isolates under sequential drug selection pressures.Characterization of the Drug Resistance Profiles of Patients Infected with CRF07_BC Using Phenotypic Assay and Ultra-Deep Pyrosequencing.Preexposure prophylaxis-selected drug resistance decays rapidly after drug cessationPopulation genomics of intrapatient HIV-1 evolutionImpact of HIV drug resistance on virologic and immunologic failure and mortality in a cohort of patients on antiretroviral therapy in China.Viral adaptation to an antiviral protein enhances the fitness level to above that of the uninhibited wild typeEstimation of the HIV-1 backward mutation rate from transmitted drug-resistant strains.HIV-1 replicative fitness in elite controllers.The high cost of fidelity.Dolutegravir-lamivudine as initial therapy in HIV-1 infected, ARV-naive patients, 48-week results of the PADDLE (Pilot Antiretroviral Design with Dolutegravir LamivudinE) studyA strong case for viral genetic factors in HIV virulence.Combination antiretroviral therapy and cell-cell spread of wild-type and drug-resistant human immunodeficiency virus-1.Impact of the N348I mutation in HIV-1 reverse transcriptase on nonnucleoside reverse transcriptase inhibitor resistance in non-subtype B HIV-1.Assessing the Paradox Between Transmitted and Acquired HIV Type 1 Drug Resistance Mutations in the Swiss HIV Cohort Study From 1998 to 2012.Factors limiting the transmission of HIV mutations conferring drug resistance: fitness costs and genetic bottlenecksReduced replication capacity of NL4-3 recombinant viruses encoding reverse transcriptase-integrase sequences from HIV-1 elite controllers.Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the Western Cape, South Africa.Ultradeep sequencing in the therapeutic management of HIV-1 infection at treatment initiation.Impact of Antiretroviral Regimens on CSF Viral Escape in a Prospective Multicohort Study of ART-Experienced HIV-1 Infected Adults in the United States.Emerging reverse transcriptase inhibitors for HIV-1 infection.
P2860
Q24234853-82BCAB99-DA7D-4B03-947B-9FB1C1ACC636Q27013917-DD3139D7-88B3-46C8-B51C-BE9250BC2009Q28474783-3AFE8AD9-88F7-493A-82C6-91F0000595F0Q28475651-36144EA2-8AB8-4070-8BBC-BBECE0EAB2F1Q28478656-08E71B31-0F69-4EAD-B6D9-663049D814E8Q28484153-69B737B5-7C3D-4E5A-9E64-99C46FDF37B7Q33748960-7855A5E9-5C28-4E5E-B89D-921E6201500BQ34054047-17D18E4D-A185-4015-A237-EA33BDA8AF55Q34148077-0D9A772D-704A-40D4-BDA1-458B13FE1167Q34615228-037EAAD7-8255-4A6D-B41C-9EEA43F4309EQ34933329-49AE1235-A8BE-4546-A333-DE9DDAE148A5Q34985572-E751967F-C332-447F-9971-AE52A2E10AF1Q35022802-D842860F-7453-4058-B17B-C96907ECE17AQ35077412-AC7BA4F0-D215-41CF-8862-73AC4836094FQ35146589-952987A6-5E67-4D1F-B0D9-DA7BBE7D15BDQ35185837-9A5DB814-08E9-45E2-A609-3AA455BAAD83Q35261045-F9E08FF8-D9DC-47F2-BF1C-1E35E4B71371Q35586657-0A20ECF7-0249-4290-B54C-863E9BF8DE76Q35798108-D1AC088E-CE5D-48EA-B32C-D9F08CC5F8F0Q35943486-757CC5DD-9052-49CF-84DD-3AC1DD29B93BQ36086642-FD6D4A75-DA89-4EED-8948-616C5970C7E2Q36255602-E9BF28B8-1511-4F38-8F8A-E53249784422Q36438778-6BD431E2-8FB6-41D6-AC6D-B7DEDDBF5D5BQ36479690-801B9D19-C6B9-4256-845E-E2B63B2C3AAAQ36959418-779467AC-01AF-4792-9ED3-7F7F4C8FC749Q37410676-7D027A61-C5BE-4EB0-86EA-242EA9CCF70CQ37447287-C03976A8-BAFD-4002-BC0D-5366F6469BD7Q37856676-D376F6D6-EA82-4DA4-A059-6E4634BC98DAQ38158093-80572BD3-9F67-4BF0-8FE5-303DEA04F39DQ38376451-234DF530-61AB-4606-8E3A-7D26367E37C8Q38615326-12D46345-AD22-45A3-8518-3744F9DA5E32Q38718627-B935FD02-F787-4451-9573-4FD12744DDB7Q39599947-749A1221-5D90-49A8-8149-B1593FCF16E2Q41551955-BA6FC115-1081-407D-8707-F9B09550D492Q42577298-3A13F0B8-60CD-4D50-8FAC-7C60D06C71B3Q42718488-1FECE0CE-93BF-44F8-914A-ACB72456A1A9Q46160580-00A7B768-1019-4A9A-A786-1D896F223430Q51064318-E90EDAF9-E815-4ABB-A2E1-A46206A9B1B7Q52607097-26BCF51D-491C-4D65-B98A-671575F19E0AQ53686168-9AE872F5-BF38-4BFD-8802-253E4E6698EF
P2860
In vivo fitness cost of the M184V mutation in multidrug-resistant human immunodeficiency virus type 1 in the absence of lamivudine.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
In vivo fitness cost of the M1 ...... in the absence of lamivudine.
@en
In vivo fitness cost of the M1 ...... in the absence of lamivudine.
@nl
type
label
In vivo fitness cost of the M1 ...... in the absence of lamivudine.
@en
In vivo fitness cost of the M1 ...... in the absence of lamivudine.
@nl
prefLabel
In vivo fitness cost of the M1 ...... in the absence of lamivudine.
@en
In vivo fitness cost of the M1 ...... in the absence of lamivudine.
@nl
P2093
P2860
P50
P356
P1433
P1476
In vivo fitness cost of the M1 ...... in the absence of lamivudine.
@en
P2093
Daniel R Kuritzkes
Jeffrey N Martin
Neil T Parkin
Rebecca Hoh
Roger Paredes
P2860
P304
P356
10.1128/JVI.02154-08
P407
P577
2008-11-19T00:00:00Z